Furthermore, our data indicate that targeting cathepsin B activity in people who have DS (i.e., an additional copy of Hsa21) is unlikely to have the same therapeutic effect as in individuals who have AD in the general population and that alternative targets should be considered for this important group of individuals who have a greatly elevated risk of early-onset disease. This evidence concerns the gene CTSB and Dravet syndrome.